Stay updated on Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page.

Latest updates to the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAn NIH site-wide notice about updates and the transition from “Artificial Intelligence” to “Super Intelligence” terminology was removed.SummaryDifference1%

- Check19 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe ClinicalTrials.gov study page continues to show a 403 Forbidden error. The footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details with an error page and indicating that the study record at this URL is inaccessible.SummaryDifference20%

Stay in the know with updates to Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page.